Sp157

PRE- AND POST-TRANSPLANT MANAGEMENT OF PATIENTS WITH PSC AND IBD

Date
May 18, 2024

Presenter


Tracks

Related Products

Thumbnail for REGIONAL MICROBIOTA MISMATCHES FROM FECAL MICROBIOTA TRANSPLANTS DRIVE PERSISTENT, OFF-TARGET CONSEQUENCES TO THE HOST
REGIONAL MICROBIOTA MISMATCHES FROM FECAL MICROBIOTA TRANSPLANTS DRIVE PERSISTENT, OFF-TARGET CONSEQUENCES TO THE HOST
Fecal microbiota transplant (FMT) is a promising, novel intervention to promote restitution and repair of colonic dysbiosis…
Thumbnail for WEARABLE PERSPIRATION SENSOR FOR CONTINUOUS INFLAMMATION TRACKING IN INFLAMMATORY BOWEL DISEASE
WEARABLE PERSPIRATION SENSOR FOR CONTINUOUS INFLAMMATION TRACKING IN INFLAMMATORY BOWEL DISEASE
Wearable sensors present an opportunity to monitor inflammation via noninvasive mediums such as perspiration, which can be sampled continuously to track inflammation-related markers in inflammatory bowel disease (IBD)…
Thumbnail for PERSISTENCE OF SPLANCHNIC GENE SIGNATURE DEFINES A TUMOR-RESTRAINING FIBROBLAST SUBTYPE IN PANCREATIC CANCER
PERSISTENCE OF SPLANCHNIC GENE SIGNATURE DEFINES A TUMOR-RESTRAINING FIBROBLAST SUBTYPE IN PANCREATIC CANCER
The pancreas is composed of the epithelial and mesenchymal cells. Interaction between the two lineages guides proper formation of the pancreas and modulates progression of pancreatic diseases such as cancer…
Thumbnail for RISANKIZUMAB EFFECTIVENESS IN USTEKINUMAB-NAIVE AND USTEKINUMAB EXPERIENCED PATIENTS WITH CHROHN'S DISEASE: REAL WORLD DATA FROM A LARGE TERTIARY CENTER
RISANKIZUMAB EFFECTIVENESS IN USTEKINUMAB-NAIVE AND USTEKINUMAB EXPERIENCED PATIENTS WITH CHROHN'S DISEASE: REAL WORLD DATA FROM A LARGE TERTIARY CENTER
<div style="direction: ltr;">BACKGROUND AND AIMS: Risankizumab and ustekinumab are both IL23 inhibitors approved the treatment of moderate to severe Crohn’s disease (CD)…